Levobetaxolol

Levobetaxolol is a potent and high affinity β-adrenergic antagonist with IC50 values of 33.2, 2970, 709 nM for guinea pig atrial β1, tracheal β2 and rat colonic β3 receptors, respectively. Levobetaxolol reduces IOP (intraocular pressure) . Levobetaxolol exhibits a micromolar affinity for L-type Ca21-channels. Levobetaxolol decreases the effects of ischaemia/reperfusion injury in rats. Levobetaxolol has the potential for the research of glaucoma[1][2].

Product Specifications

CAS Number

[93221-48-8]

Product Name Alternative

(S) -Betaxolol

UNSPSC

12352005

Hazard Statement

H315-H319-H320

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/levobetaxolol.html

Solubility

10 mM in DMSO

Smiles

O[C@H](COC1=CC=C(C=C1)CCOCC2CC2)CNC(C)C

Molecular Formula

C18H29NO3

Molecular Weight

307.43

Precautions

P264-P280-P302+P352-P305+P351+P338-P362

References & Citations

[1]Sharif NA, et al. Levobetaxolol (Betaxon) and other beta-adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes. J Ocul Pharmacol Ther. 2001 Aug;17 (4) :305-17.|[2]Osborne NN, et al. Effectiveness of levobetaxolol and timolol at blunting retinal ischaemia is related to their calcium and sodium blocking activities: relevance to glaucoma. Brain Res Bull. 2004 Feb 15;62 (6) :525-8.